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Abstract: Glucose consumption in many types of cancer cells, in particular hepatocellular carcinoma
(HCC), was followed completely by over-expression of type II hexokinase (HKII). This evidence has
been used in modern pharmacotherapy to discover therapeutic target against glycolysis in cancer
cells. Bromopyruvate (BrPA) exhibits antagonist property against HKII and can be used to inhibit
glycolysis. However, the clinical application of BrPA is mostly combined with inhibition effect for
healthy cells particularly erythrocytes. Our strategy is to encapsulate BrPA in a selected vehicle,
without any leakage of BrPA out of vehicle in blood stream. This structure has been constructed from
chitosan embedded into oleic acid layer and then coated by dual combination of folic acid (FA) and
bovine serum albumin (BSA). With FA as specific ligand for cancer folate receptor and BSA that can
be an easy binding for hepatocytes, they can raise the potential selection of carrier system.
Keywords: nanocarrier; glycolysis; hepatocellular carcinoma (HCC); bromopyruvate
1. Introduction
Increase of glucose consumption in many types of cancer cells is supported mostly
by overexpression of type II hexokinase (HKII) [1]. Hence, Hexokinase (ATP: D-hexose
6-phosphotransferase) is a key enzyme that catalyzes the first step in the glycolysis pathway.
This enzyme transfers a phosphate group from ATP to glucose to form glucose-6-phosphate [2].
Moreover, HKII interacts with the outer membrane protein voltage dependent anion channel
(VDAC). It blocks mitochondrial inter-membrane space protein release and prevents activation of the
apoptotic process [3]. This unique property has gained attention from researchers to develop new
chemotherapeutic strategies targeting the glycolysis pathway in cancer cells [4]. Various inhibitors
affecting the key enzymes of the glycolysis pathway have been identified. Among the glycolytic
inhibitors, bromopyruvate (BrPA) shows promising anticancer activity both in vitro and in vivo.
Indeed, BrPA causes regression of solid tumors by ATP depletion [5]. It has, furthermore, been shown
to be effective and, indeed, curative, as a single agent against hepatic tumors in animal models [5].
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The crucial problem for using BrPA in clinical application is related to its interaction with normal
cells, especially erythrocytes [6]. Thus, there is an urgent need to encapsulate BrPA inside smart
carriers having efficient strategies from size, shape, and targeted for cancer cells. In our previous
report, BrPA attached Poly(allylamine) hydrochloride was entrapped inside CaCO3 rods during their
fabrication. Encapsulated BrPA was absorbed by cancer cells and, furthermore, was released gradually
with time as demonstrated by confocal microscopy and MTT assay [7]. However, non-specific, passive,
targeting carriers can result in uptake by healthy cells. This can be minimized by the active targeting of
the therapy, which has not been explored previously by this team. In our recent work, targeted hybrid
lipid polymer is fabricated as an alternate assembly structure instead of liposomes. Their positive
attributes (such as their tunable size, surface charge, high drug loading yield, sustained drug release
profile, favorable stability in serum, good cellular targeting ability) make them a promising drug
delivery vehicle for further in vivo tests. Hybrid polymeric protein carriers (HPPNCs) were assembled
by using chitosan, oleic acid, and BSA-FA to produce a core-shell structure.
Chitosan is a copolymer of β-(1→4)-linked-2-acetamido-2-deoxy-D-glucopyranose and
2-amino-2-deoxy-D-glucopyranose [8]. Its unique properties, such as biodegradability, biocompatibility,
nontoxicity, positively-charged, and rigid linear molecular structure make this macromolecule ideal
as a drug carrier and delivery material [9]. Chitosan is soluble in aqueous solutions of various
acids, but chitosan molecules have no amphiphilic property and cannot produce micelles in water.
Thus, there are many reports on hydrophobic changes of chitosan, for example, palmitoyl glycol
chitosan [10], deoxycholic acid-modified chitosan, [11], poly(N-isopropylacrylamide)-chitosan [12],
linoleic acid-modified chitosan [13], linolenic acid modified chitosan [14], N-alkyl-O-sulfate
chitosan [15], chitosanpolylactide graft copolymer [16], N-acetylchitosan, N-propionylchitosan, and
N-butyrylchitosan, butanoylchitosan, hexanoy-chitosan, and benzoyl-chitosan [17]. Bovine serum
albumin (BSA) is biodegradable, biocompatible, nontoxic, and not immunogenic [18], making it an
ideal delivery carrier for drugs. In particular, BSA-based nanoparticles (NPs) might cause natural
abundance in plasma, relative stability and inertness in biochemical pathways, availability, and
a relatively benign in vivo biological fate [19]. A tumor-targeting agent, folic acid, was linked to
BSA to increase the selective targeting ability of the conjugate [20]. Folic acid has been widely
used as a ligand for folate receptor-mediated selective targeting and delivery of drugs into tumor
cells [21]. The folate receptor has been found to be overexpressed in a wide range of tumors, and is
known as a high-affinity membrane folate-binding protein, which mediates uptake of the vitamin
by receptor-mediated endocytosis [22]. Recently, maximum entrapment efficiency investigation
of similar systems was also performed [23] and use of SiRNA for following oral administration of
chitosan/SiRNA nanoparticles was further investigated [24]. In a previous paper, we have investigated
conjugation of folic acid with BSA. Whereas prior to the conjugation to BSA, FA was activated by
using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDAC) and NHS to trigger the binding of
the carboxyl group (specifically the gamma-COOH) of FA to the free amino moieties of BSA [25].
The novelty of this work is to obtain nucleus made up of chitosan-oleic acid. Since the hydrophobic
modification of chitosan that was done by coupling with fatty acid, can result in product with an
amphiphilic behavior and self-aggregation. Then oleic acid grafted chitosan was inserted into a layer
of albumin-FA to achieve higher drug levels in tumor tissue and to minimize side effects.
2. Results and Discussion
2.1. Characterization
Oleic acid is a mono-unsaturated fatty acid. It is able to generate reactive oxygen species (ROS)
inside cells because it has free fatty acids with anti-neoplastic properties against cancer cells [26].
In this study, the active site of free fatty acid was blocked by dissolving oleic acid in alcohol [27]
(e.g., in this study, ethanol was used). It was then heated for 2 h at 60 ◦C. Afterwards EDAC was
added to activate the carboxylic group of oleic acid (see Figure 1) resulting in a homogenous esterified
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suspension [28]. Oleic acid (OA) was coupled to chitosan by the formation of amide linkages through
the EDAC-mediated reaction with different degrees of amino substitution (DS) as described in a
previous study [29] (see Figure 1, Step 1). Although chitosan molecules present no amphiphilic
property and, therefore, cannot form micelles in water, chitosan chains can be modified by oleic acid
by means of the introduction of carboxylic acid groups in the presence of water-soluble carbodiimide,
which react with carboxyl groups of fatty acids, forming active ester intermediates. Consequently,
the intermediates can react with primary amine groups of chitosan to create an amide bond. The final
product of this assembly is a nano-sized self-aggregation in aqueous media [30]. These nuclei were
made up of self-aggregated chitosan and oleic acid was coated by FA conjugated with BSA to target
cancer cells and to minimize side effects [22].
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The zeta potential of nanoparticles assembled by oleic acid-grafted chitosan showed good 
adsorption (81 ± 1.5 mV) (see Figure 2C) compared to chitosan alone and oleic acid alone. The results 
show a significant reduction of the potential surface of NPs after their fabrication, indicating that 
BSA-FAwas assembled up to surface of OA-grafted chitosan.  
This result confirms the stability of this colloidal suspension for biological and environmental 
applications [31]. Additionally, it is a real indication for the combination of these dual structures 
compared to the zeta potential of both chitosan alone and oleic acid alone (see Figure 2A,B). 
Dynamic light scattering (DLS) investigation was also performed to gain evidence of the differences 
in the size of the materials used (see Figure S1 in the Supplementary Materials). 
The distribution of used materials such as chitosan alone, oleic acid alone, oleic acid-grafted 
chitosan, and hybrid polymeric lipid protein micro/nano-particles on a scale bar were studied by 
DLS to describe the modification of the material size that was used during the experiment. The given 
Figure 1. Scheme of hybrid polymer lipid protein nanocarrier structure. Step 1: self-assembly Structure
of chitosan and oleic acid; step 2: conjugation folic acid with bovine serum albumin; and step 3:
functionalization of chitosan grafted oleic acid surface by using BSA-FA.
The zeta potential of nanoparticles assembled by oleic acid-grafted chitosan showed good
adsorption (81 ± 1.5 mV) (see Figure 2C) compared to chitosan alone and oleic acid alone. The results
show a significant reduction of the potential surface of NPs after their fabrication, indicating that
BSA-FAwas assembled up to surface of OA-grafted chitosan.
This result confirms the stability of this colloidal suspension for biological and environmental
applications [31]. Additionally, it is a real indication for the combination of these dual structures
compared to the zeta potential of both chitosan alone and oleic acid alone (see Figure 2A,B). Dynamic
light scattering (DLS) investigation was also performed to gain evidence of the differences in the size
of the materials used (see Figure S1 in the Supplementary Materials).
The distribution of used materials such as chitosan alone, oleic acid alone, oleic acid-grafted
chitosan, and hybrid polymeric lipid protein micro/nano-particles on a scale bar were studied by
DLS to describe the modification of the material size that was used during the experiment. The given
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result indicates that chitosan and oleic acid have high distributions before assembling and their
complexes improve their uniformity. Hence, the polydispersity value (PDI) reflects the nanoparticle
size distribution. In our study, PDI mostly ranged from 0.6 to 1. This wide range of values is
closely related to the number of carboxyl groups of OA and the primary amino group of chitosan
assembled together.
For the purpose of targeted delivery, the surface of NPs was also functionalized with FA
conjugated to BSA. Their potential surface was modified after conjugation and measured at
18.6 ± 0.8 mV (see Figure 2D). This result indicates that the surface of OA-integrated chitosan was
actually coated by a BSA-FA layer. Data of the BSA functionalized with FA was already published [25].
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Figure 2. Zeta potential measurement: (A) chitosan solution alone; (B) oleic acid suspension alone;
(C) chitosan grafted oleic acid; and (D) Hybrid Polymeric Lipid Protein Nanocarriers (HPLPNCs).
In order to characterize the structure of the hybrid nano-lipid, NPs were stained by uranyl
acetate to enhance OA electron density and then imaged by Transmission Electron Microscopy (TEM).
The results show a dim ring structure surrounding the core (see Figure 3) and three or four layers were
completely attached having diameters of 30–60 nm [27]. These results indicated that the hydrophobic
modified chitosan was well dispersed in aqueous media, with an increase in the amide linkage
between chitosan and OA, and a denser hydrophobic core was formed [32]. These modifications can
introduce hydrophobic groups into chitosan and form amphiphilic chitosan polymers. Some of these
amphiphilic chitosan polymers can generate nano-sized self-aggregation in aqueous media [30]. In this
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study chitosan chains were modified by oleic acid through the introduction of the carboxylic acid
group in the presence of water-soluble carbodiimide, which reacts with the carboxyl groups of fatty
acids forming active ester intermediates. Consequently, the intermediates can react with primary
amine groups of chitosan to form an amide bond (see scheme Figure 1).
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Figure 3. Transmission Electron Microscopy (TEM) characterization: (A) low magnification of
HPLPNCs; and (B) high magnification view of HPLPNCs. Scale bars: 250 nm.
The NP furthermore comprises three distinct functional components: (i) a hydrophobic polymeric
core where chitosan was successfully entrapped inside the core and it was the main place for drug
encapsulation; (ii) a hydrophilic BSA-FA shell with a delivery targeting purpose and for good liver cell
binding; and (iii) a lipid monolayer at the interface of the core and the shell that acts as a molecular
fence to prevent drug leakage, thereby enhancing drug encapsulation efficiency, increasing drug
loading yield, and controlling drug release [33]. Moreover, the fluorescein isothiocyanate (FITC)
marker integrated inside carrier moieties shows good fluorescein intensity (see Figure 4A,B). However,
the intensity of FITC-labeled HPPNCs was observed by fluorescence spectroscopy showing a peak at
520 nm. Similarly, the peak emerged by FITC integrated chitosan-oleic acid moieties. Figure 4C shows
that intracellular nanoparticle uptake occurred after post-cell treatment. Hence, FITC-HPPNC was
visualized as a green color distributed inside the cytoplasm. Cellular uptake study using FITC-labeled
HPPNCs showed that cancer cells readily accumulate the nanoparticles within cells for up to 24 h
post treatment. According to Equation (1), high-resolution mass spectrometry shows good results for
the encapsulation of BrPA (see Figure 5) into the NPs. Quantitative calculations provide a loading
efficiency of about 0.45 mg/mL and a percentage of loading of about 45%.
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HPLC-HRMS chromatograms of BrPA befor ( l ) and after (red) loading. Th peak area was
obtained from the extracted ion chromatogram (EIC) with m/z 164.9193 corresponding to the molecular
ion [M − H]− of BrPA. The peak obtained after loading refers to BrPA concentration in the supernatant
after centrifugation.
2.2. Cellular Experiments
The cellular internalization of hybrid polymeric lipid protein carriers was measured by
fluoresc nce mic oscopy. H nce, FITC-labeled carriers are successfully localized inside cytoplasm
and emitted gre n color ( e Figure 4C). The optical density measurements give an indication of the
relative viable cells present at th time th dye is added.
In this study, crystal violet was used to investigate the morphological characterization for all
experimental conditions. Ethidium bromide was also used to show hyperchromatism and apoptotic
bodies. Crystal violet (CV) is a triphenylmethane dye known as gentian violet, utilized widely
to measure cell viability [34] or cell proliferation [35] under different conditions. Crystal violet
can enter the cell membrane and reacts with cytoplasmic protein structures, distinguish between
cytoskeleton and nuclear morphology. The morphological structure of either HLF cells incubated
in normal conditions or that were incubated with free Hybrid Polymeric Lipid Protein Nanocarriers
HPLPNCs a peared in well-organized structures with intact nuclei (see Figure 6). Most of the HLF
cells incubated with free BrPA or encapsulated BrPA exhibited round and condensed structures with
apoptotic morphology.
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Ethidium bromide, a DNA binding dye, stains those cells that have lost their nuclear membrane
integrity [36]. It is commonly used to visualize nuclear membrane disintegration and apoptotic body
formations that are characteristic of apoptosis.
In Figure 7 control HLF cells and free HPLPNC showed rounded nucleus with one or more
nucleoli. On the other side, hyper chromatic cells were characterized by the condensed yellow color
in both free BrPA and encapsulated BrPA groups, in addition to apoptotic bodies, were seen in
encapsulated BrPA slides.
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Figure 7. Hyperchromatism and apoptotic bodies: (A) control HLF; (B) free HPLPNCs; (C) free BrPA;
and (D) encapsulated BrPA. Arrows indicate apoptotic bodies.
Trypan blue is one of the most commonly used methods for assessment of viability in a given cell
population [37,38]. It is used in our study to quantify dead cells by spectrophotometry at 570 nm [31].
Optical analysis of the cultures revealed an admixture of live (trypan blue negative) and dead (trypan
blue positive) in experimental condition. In Figure 8 the cell mortality measured by trypan blue assay
was increased in case of free BrPA and also encapsulated BrPA, compared to control HLF cells and
cells treated by free HPLPNC (capsules). Furthermore, upon increasing the treatment time (from
3 to 6 to 24 h) there is also a clear increase in cell death. In our previous work [25], and in this
study, are reported the potential therapeutic effectiveness of targeted nanoparticles against cancer cells
since they can allow smart chemotherapeutics to be accumulated in specific tumor sites, in order to
minimize the potential side effects of chemotherapies on healthy cells, too. These advantages have
received significant attention due to the overexpression of specific receptors, antigens, and molecules
on cancer cell membrane. These molecules can be recognized by nanoparticles that were designed
by folic acid [25], transferrin [39], short oligonucleotides of RNA or DNA that can fold into various
conformations and engage in ligand binding [40], specific antibodies [41], and peptides [42].
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Figure 8. Trypan blue spectrophotometrical viability analysis against HLF cells. Percentage of dead
cells upon increasing time (3–6–24 h) after treatment with free HPLPNC, free BrPA and encapsulated
BrPA are reported. Data showed is an averaged value of three successive measurements with standard
deviation (S.D.).
3. Materials and Methods
3.1. Chemicals
Chitosan oligosaccharide ( olecular eight ( ) 5kDa), oleic acid, and
1-ethyl-3-(3-di ethyla inopropyl) carbodii ide (EDAC), di ethyl sulfoxide (D SO),
bro opyruvate, bovine serum albumin, folic acid, trypan blue, crystal violet, and ethiduim
bromide were purchased from Sigma-Aldrich (Milan, Italy).
◦ fl t .
t ti f i .
: g of folic acid was dissolved in 2.5 mL of DMSO for 30 min. Then 30 mg of EDAC and
38 mg of NHS were adde , completing rotation f r 1 h. Afterwards 4 mg of BSA were dissolved in
50 mL of distilled water in the pr sence of EDAC for 30 min. At the end 0.5 mL of activated FA mixed
with 25 mL of activated BSA under rotation for 30 min.
i . Then the mixture was centrifuged at 500 rpm for 30 min at 20 ◦C. Afterwards the upper lay
was separated and dissolved in 10 mL Milli Q water and the mixture was dialyzed ag inst milli Q
water overnight.
3.3. haracterizatio
3.3.1. Transmission Electron Microscopy (TEM)
Samples for TEM analysis were obtained by drop-casting a few microliters of solution onto
standard TEM carbon-coated Cu-grids, and by allowing the solvent to fully evaporate. Samples were
imaged by using a JEOL JEM 1011 TEM microscope (JEOL, Inc., Peabody, MA, USA) operating at
100 kV.
3.3.2. Fluorescence Spectrophotometry
The intensity of fluorescence markers was detected by Cary Eclipse fluorescence
spectrophotometer (Agilent, Santa Clara, CA, USA). The analysis was performed on the following:
chitosan integrated oleic acid-FITC and free hybrid assembly.
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3.3.3. Zeta Potential Measurements
The zeta potential surface of carrier fabrication was measured by using a Malvern Nano ZS90
(Malvern Instruments, Malvern, UK). An average of five successful runs was considered for analysis.
3.3.4. Quantification of BrPA loaded HPLPNCs by Using HPLC-Mass Spectrometry (HPLC-MS)
Briefly, BrPA solution of known concentration was incubated overnight with HPLPNCs. Then,
the supernatant was removed by centrifugation and it was analyzed by high-resolution liquid
chromatography coupled to mass spectrometry (HPLC-HRMS). The loading percentage was defined
as the residual BrPA moles in solution after loading divided by the moles of BrPA in solution before
loading. In particular the encapsulation efficiency (% loading) was calculated as the relative difference
between 3-BrPA concentrations before and after the incubation experiment (see Equation (1)).
% Loading = 100 × ([BrPA]i− [BrPA]f)/[BrPA]i (1)
[BrPA]i is defined as the initial concentration of BrPA, [BrPA]f is defined as the final concentration of
BrPA. HPLC-HRMS experiments were performed with an Agilent 6540 quadruple time-of-flight (QToF)
mass spectrometer (Agilent, Santa Clara, CA, USA) equipped with an electrospray ionization (ESI)
source and interfaced to an Agilent 1200 modular high-performance liquid chromatograph consisting
of a binary pump, a vacuum degasser, a thermostated autosampler, and a thermostated column
compartment. The following general conditions were adopted: ESI source operating in negative mode;
solvent: 80% water (0.1% formic acid) and 20% acetonitrile; flow rate: 0.2 mL·min−1; drying gas (N2):
11 L·min−1; nebulizer pressure: 45 psi; drying gas temperature: 350 ◦C; capillary voltage: 4000 V;
fragmentor: 150 V; mass range: 50–1600 m/z. Mass spectrometry chromatograms were acquired and
analyzed using Agilent Mass Hunter Qualitative Analyses version B.01.04 data processing software
(Agilent, Santa Clara, CA, USA). A four non-zero point calibration curve was built for BrPA by plotting
the concentration of the analytical standard in aqueous solution (0.1, 0.2, 0.5, and 1.0 mg/mL) against
and the peak area of the m/z 164.9193 corresponding to the extracted ion chromatogram (EIC) of BrPA.
The calibration equation was: y = 5·106 x + 495,851 with a coefficient of determination R2 = 0.9979.
3.4. Cellular Experiments
3.4.1. Cellular Studies
HLF cell lines were purchased as described in [43,44] and were maintained in DMEM medium
supplemented with FBS (10%), penicillin (100 U·mL−1 culture medium), streptomycin (100 mg·mL−1
culture medium), and glutamine (5%). Cells were grown in an incubator at 37 ◦C, under 5% CO2, and
at 95% relative humidity. Cell lines were serum-starved for 24 h before any test.
3.4.2. Cellular Uptake
HLF Cell lines were seeded on sterilized glass coverslips into petri dishes, with a density of
2000 cells. They were grown under normal condition as previously described. After 24 h, 100 µL
of hybrid assembly were added. Cellular uptake was measured after the next 24 h incubation by
fluorescence microscopy.
3.4.3. Crystal Violet
Ten thousand HLF cells were seeded in 24 multi-wells and grown as previously described. After
24 h, cells were added with 100 µL of free hybrid lipid nanoparticles, or with free BrPA or with
encapsulated BrPA and incubated for additional 24 h. Then, DMEM was discharged and cells were
washed three times with phosphate buffered saline PBS (pH 7.2). Cells were fixed for 15 min with
buffered formalin (3.7%), extensively washed with PBS (pH 7.3), and finally stained with 0.01% crystal
violet in PBS. After removing excess stain, cells were incubated at PBS (pH 7.3). Optical images
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were captured in the bright field by using a fluorescence microscope (TCS SP5; Leica, Microsystem
GmbH, Mannheim, Germany) equipped with a digital camera (Leica, Microsystem GmbH, Mannheim,
Germany).
3.4.4. Ethidium Bromide (EB)
Cells were washed with 1× PBS buffer (pH 7.4), fixed with absolute methanol for 10 min, and
washed again with 1× PBS buffer (pH 7.4). Cells were stained with 50 µL of EB (100 µg/mL) for
10–15 min and then they were immediately washed with PBS and observed under a light microscope.
3.4.5. Trypan Blue
According to procedure used by Uliasz and Hewett, 2007 [12], 50 mL of sterile 0.4% trypan blue
solution (final concentration 0.05%) was added to each culture well and the plate placed back into the
incubator (37 ◦C) for 15 min. Then dye-containing media was gently removed by washing (3× 750 mL)
with ice-cold phosphate buffered saline (0.01 M PBS). A slow, steady wash prevents loss of injured
cells that may originate from mechanical handling. Visual analysis of the cultures showed a mixture
of live (trypan blue negative) and dead (trypan blue positive) cells in each experimental condition.
Cells were then lysed with 200 mL of sodium dodecyl sulfate (SDS; 1% w/v) and the contents gently
fractured taking care not to introduce air bubbles. At the end, 175 mL of the SDS: trypan blue solution
was transferred to a 96-well culture dish and measured spectrophotometrically at 590 nm.
4. Conclusions
Chitosan-grafted OA was used as a vehicle to encapsulate BrPA through electrostatic reaction
of amino–hydroxyl groups. Hence, the OA layer acts as a molecular fence to prevent drug release.
Finally HPLPNCs were fabricated with smart properties, such as nano-sized diameter, spherical shape,
control drug release properties, good drug capacity, and dual combination targeting. Crystal violet
and ethidium bromide results confirm efficiency of encapsulated BrPA, compared to HPLPNCs alone.
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